10/26/2026
In a 2017 randomized, double-blind, placebo-controlled clinical trial published in the Iranian Journal of Psychiatry, researchers studied 34 patients aged 10–21 with OCD over 10 weeks. Participants received standard antidepressant medication alongside either NAC or a placebo. NAC supplementation began at 600 mg daily and gradually increased to a maximum of 2,400 mg daily by week six. By the end of the study, average OCD symptom severity scores in the NAC group had decreased from 21.0 to 11.3, representing an approximately 46% reduction. In comparison, scores in the placebo group decreased from 22.5 to 19.7, an approximately 12% reduction. Improvements in the NAC group were observed as early as week four, and participants also showed better control over compulsive behaviors. No serious adverse effects were reported.
Obsessive-compulsive disorder (OCD) is a mental health condition characterized by recurring, unwanted thoughts (obsessions) and repetitive behaviors or mental rituals (compulsions). These symptoms can interfere with daily activities, school performance, relationships, and quality of life. Standard treatments include cognitive behavioral therapy (CBT), particularly exposure and response prevention, and antidepressant medications known as selective serotonin reuptake inhibitors (SSRIs). However, some children and adolescents continue to experience significant symptoms despite treatment. N-Acetylcysteine (NAC) is a compound that helps the body produce glutathione, an important antioxidant, and may influence glutamate signaling in the brain. Because glutamate is involved in brain circuits associated with repetitive thoughts and behaviors, researchers have investigated NAC as a potential additional treatment for OCD.
In a 2017 randomized, double-blind, placebo-controlled clinical trial published in the Iranian Journal of Psychiatry, researchers studied 34 patients aged 10–21 with OCD over 10 weeks. Participants received standard antidepressant medication alongside either NAC or a placebo. NAC supplementation began at 600 mg daily and gradually increased to a maximum of 2,400 mg daily by week six. By the end of the study, average OCD symptom severity scores in the NAC group had decreased from 21.0 to 11.3, representing an approximately 46% reduction. In comparison, scores in the placebo group decreased from 22.5 to 19.7, an approximately 12% reduction. Improvements in the NAC group were observed as early as week four, and participants also showed better control over compulsive behaviors. No serious adverse effects were reported.